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Conclusion  
The proposed plan QA tool can detect outliers with an 
accuracy of 3-4Gy and 2%-3% (90% CI). Totally 13/46 (28%) 
of the automatically generated plans were outliers. 
Indeed, for all of them re-planning resulted in an improved 
plan. This emphasizes the need for treatment planning 
QA, also for automated treatment planning. For manual 
treatment planning, the percentage of outliers is 
expected to be higher and therefore treatment planning 
QA is even more important. 
   
OC-0255  Practical use of principal component analysis 
in radiotherapy planning  
D. Christophides1, A. Gilbert2, A.L. Appelt2,  J. Fenwick3, 
J. Lilley4, D. Sebag-Montefiore2   
1Leeds CRUK Centre and Leeds Institute of Can cer and 
Pathology, University of Leeds, Leeds, United Kingdom 
2Leeds Institute of Cancer and Pathology - University of 
Leeds and Leeds Cancer Centre, St James’s University 
Hospital, Leeds, United Kingdom 
3Institute of Translational Medicine, University of 
Liverpool, Liverpool, United Kingdom 
4Leeds Cancer Centre, St James’s University Hospital, 
Leeds, United Kingdom 
 
Purpose or Objective   
Principal component  analysis (PCA) is a promising 
technique for handling DVH data in NTCP modelling. 
However it is challenging to interpret its results clinically 
and use them to make informed decisions for specific 
patients. A method is developed that uses PCA-based 
NTCP modelling to produce treatment optimisation 
objectives which can be used for treatment plan 
improvement. The utility of the method is demonstrated 
in a treatment planning case as well as in a simulation 
study, for reducing predicted patient reported outcome 
(PRO) scores of vaginal stenosis. 
Material and Methods  
Data from 221 female patients treated with pelvic 
radiotherapy were made available from a larger study 
(DRF-2012-05-201) on optimising patient outcomes. 
Vaginal stenosis PRO scores (“Has your vagina felt tight?”: 
“Not at all” (0), “A little” (1), “Quite a bit” (2) and “Very 
much” (3)) were completed by 74 (29%) patients. The 
principal components (PCs) extracted from the available 
external genitalia DVHs, along with clinical factors, were 
used to construct an ordinal logistic regression model that 
predicted the probability of patients having vaginal 
stenosis  symptoms. 
The model identified age, hormone replacement therapy 
and the first PC (PC1) as important predictors of vaginal 
stenosis PRO scores. Based on the model, the probability 
of grade 2 or greater PRO score could be calculated; as 
well as a PC1 that could theoretically reduce that 
probability by 50% (PC1'). PC1' was used to derive a PCA-
modified DVH' using the following method: i) the modified 
principal components were inversely transformed into the 
DVH domain to obtain a new DVH', ii) DVH' was cropped so 
the volumes were always greater than 0% and lower than 
the original DVH, and iii) DVH' was made monotonically 
decreasing.  
An anal cancer patient case was planned using VMAT and 
the PCA-based model information, as a demonstration of 
the clinical applicability of PCA-based modelling. The 
method was then used to modify the DVHs of all available 
patients (N=221). The probability of having grade 2 ≥ PRO 
scores using the un-modified patient DVH and the PCA-
modified DVH' were compared using a paired t-test. 
Results  
The treatment planning case demonstrated the clinical 
relevance of PCA-based modelling by using PCA 
information to formulate cost functions to reduce the dose 
to the genitalia (Fig.1), which resulted in a reduction of 
the predicted probability of vaginal stenosis symptoms 
(Fig.2). The simulation results showed a statistically 
significant decrease in the probability of having grade 2 ≥ 
PRO scores (Reduction in mean = 33%, p<0.001).  
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Conclusion  
The method presented allows for the use of PCA-based 
NTCP modelling to optimize patient DVHs to improve 
treatment plans. The clinical applicability of the method 
was tested on a treatment planning case, with a reduction 
of the predicted probability of vaginal stenosis symptoms. 
Furthermore simulation results showed a potential 
significant reduction of grade ≥2 vaginal stenosis PRO 
scores. 
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Purpose or Objective  
The decision to treat a patient with protons or photons is 
currently based upon the dosimetry of both plans and, for 
example, whether proton plans reduce dose to organs at 
risk (OAR) or the estimated toxicity by a pre-determined 
threshold. However, creation of two treatment plans (TPs) 
is time intensive, and plans can vary in quality due to 
patient-specific choices, planning experience and 
institutional-protocols. RapidPlanTM, uses a TP library to 
predict dose-volume histograms (DVHs) and can generate 
Knowledge Based Plans (KBPs). We investigated 1) 
whether RapidPlan, currently designed for photons, could 
also generate proton KBPs and 2)  if predicted DVHs alone, 
could provide an efficient and objective way to select 
patients for proton therapy. 
Material and Methods  
Thirty proton and photon TPs for head and neck cancer 
patients populated proton and photon model-libraries, 
and were used to create DVH predictions and KBPs for 10 
evaluation patients. Accuracy of DVH-predicted OAR mean 
dose (Dmean) was assessed by comparison with achieved 
Dmean of KBPs. KBPs were compared with manually 
optimized TPs using target homogeneity and Dmean of 
composite salivary (compsal) and swallowing (compswal) 
organs. To illustrate how patients might be selected for 
protons, the Dmean of the contralateral submandibular, 
average parotid glands and volume weighted swallowing 
structures were summated, and protons were selected if 
the model-predicted proton minus photon Dmean 
(∆Prediction) was ≥6Gy (arbitrarily chosen). A correction 
was applied to account for inaccuracies in predictions (see 
below). Selection was benchmarked with differences 
between proton and photon KBPs achieved Dmean. 
Results  
R2 values between achieved and predicted Dmean were 0.95 
and 0.98 using proton and photon models, respectively 
(Figure). On avarage, photon KBPs resulted in 1.3Gy lower 
Dmean and proton KBPs 0.8Gy higher than predicted, 
however one patient exhibited >10Gy difference with the 
proton model. On average there was <2Gy difference 
between KBPs and manual TPs for compsal and compswal 
Dmean, and <2% for target homogeneity. Using ∆Prediction 
≥6Gy correctly selected 4/5 patients for protons. 
Generating DVH-predictions and optimizing proton KBPs 
typically took <45 seconds and 3 minutes, respectively. 
 
 
 
Conclusion  
Once model libraries have been created, comparing 
knowledge-based DVH-predictions allows rapid patient 
selection for protons without the need to create TPs, 
minimizing subjectivity and the use of resources. 
Discrepancies between predicted and achieved Dmean for 
proton KBPs may have been due to the relatively small 
model libraries and the fact that the current RapidPlan 
algorithm is designed for photons. A proton-specific 
platform may address some of the shortcomings. 
Conversion of predicted DVH to estimated normal tissue 
complication probability, could further enhance the 
comparative process. 
 
 
Proffered Papers: Best of online MRI-guided 
radiotherapy  
 
 
OC-0257  Comprehensive MRI Acceptance Testing & 
Commissioning of a 1.5T MR-Linac: Guidelines and 
Results 
R.H.N. Tijssen1, S.P.M. Crijns1, J.J. Bluemink1, S.S. 
Hacket1, J.H.W. DeVries1, M.J. Kruiskamp2, M.E.P. 
Philippens1, J.J.W. Lagendijk1, B.W. Raaymakers1 
1UMC Utrecht, Department of Radiation Oncology, 
Utrecht, The Netherlands 
2Philips Healthcare, MR Therapy, Best, The Netherlands 
